Last reviewed · How we verify
Duac® fixed dose combination gel
Duac combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to kill acne-causing bacteria and reduce inflammation.
Duac combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to kill acne-causing bacteria and reduce inflammation. Used for Acne vulgaris.
At a glance
| Generic name | Duac® fixed dose combination gel |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Topical antibiotic combination |
| Target | Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, while benzoyl peroxide generates reactive oxygen species that have bactericidal activity against Propionibacterium acnes. Together, they provide synergistic antimicrobial and anti-inflammatory effects on acne lesions.
Approved indications
- Acne vulgaris
Common side effects
- Skin irritation
- Dryness
- Erythema
- Peeling
- Contact dermatitis
Key clinical trials
- DUAC® Early Onset Efficacy Study in Japanese Subjects (PHASE4)
- Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Duac® fixed dose combination gel CI brief — competitive landscape report
- Duac® fixed dose combination gel updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI